X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (938) 938
Publication (92) 92
Book Chapter (9) 9
Data Set (2) 2
Patent (2) 2
Book Review (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (383) 383
humans (375) 375
oncology (270) 270
male (263) 263
cancer (204) 204
middle aged (202) 202
aged (199) 199
female (185) 185
urology & nephrology (158) 158
carcinoma, renal cell - drug therapy (132) 132
kidney neoplasms - drug therapy (129) 129
urology (127) 127
survival (121) 121
care and treatment (107) 107
sunitinib (102) 102
carcinoma, renal cell (101) 101
kidney neoplasms - pathology (99) 99
treatment outcome (99) 99
metastasis (97) 97
article (95) 95
prognosis (94) 94
adult (92) 92
renal cell carcinoma (87) 87
aged, 80 and over (83) 83
risk factors (77) 77
antineoplastic agents - therapeutic use (76) 76
retrospective studies (73) 73
prostate cancer (71) 71
hematology, oncology and palliative medicine (66) 66
interferon-alpha (66) 66
abridged index medicus (65) 65
carcinoma, renal cell - pathology (65) 65
analysis (62) 62
disease-free survival (61) 61
sorafenib (59) 59
carcinoma (56) 56
tumors (55) 55
carcinoma, renal cell - mortality (52) 52
neoplasm metastasis (52) 52
everolimus (51) 51
therapy (51) 51
health aspects (50) 50
targeted therapy (50) 50
kidney neoplasms - mortality (49) 49
kidney cancer (48) 48
vascular endothelial growth factor (46) 46
bevacizumab (45) 45
neoplasm staging (45) 45
research (45) 45
risk (45) 45
carcinoma, renal cell - secondary (44) 44
medical colleges (42) 42
mortality (42) 42
chemotherapy (41) 41
immunotherapy (41) 41
carcinoma, renal cell - genetics (38) 38
kidney neoplasms - genetics (38) 38
patient outcomes (38) 38
patients (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
clear cell-type renal cell carcinoma (36) 36
survival analysis (36) 36
trial (36) 36
radical prostatectomy (35) 35
survival rate (35) 35
vascular endothelial growth factor a - antagonists & inhibitors (35) 35
kaplan-meier estimate (33) 33
men (33) 33
molecular targeted therapy (33) 33
outcomes (33) 33
proportional hazards models (33) 33
prostatic neoplasms - therapy (33) 33
indoles - therapeutic use (31) 31
pyrroles - therapeutic use (31) 31
radiotherapy (31) 31
time factors (31) 31
usage (31) 31
mutation (30) 30
risk assessment (30) 30
diagnosis (29) 29
antineoplastic agents - adverse effects (28) 28
double-blind (28) 28
drug therapy (28) 28
protein kinase inhibitors - therapeutic use (28) 28
seer program (28) 28
follow-up studies (27) 27
metastases (27) 27
pazopanib (27) 27
angiogenesis inhibitors - therapeutic use (26) 26
antineoplastic agents (26) 26
databases, factual (26) 26
kidney neoplasms - metabolism (26) 26
open-label (26) 26
prostatic neoplasms - pathology (26) 26
united states (26) 26
bladder cancer (25) 25
expression (25) 25
niacinamide - analogs & derivatives (25) 25
randomized controlled trials as topic (25) 25
carcinoma, renal cell - metabolism (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
NATURE REVIEWS CLINICAL ONCOLOGY, ISSN 1759-4774, 02/2017, Volume 14, Issue 2, pp. 82 - 84
In 2016, two major trials provided conflicting evidence regarding the role of 1 year of adjuvant therapy with sunitinib for patients with high-risk renal-cell... 
CABOZANTINIB | MULTICENTER | EVEROLIMUS | ONCOLOGY | HIGH-RISK | PHASE-3 TRIAL | OPEN-LABEL | NIVOLUMAB | RENAL-CELL CARCINOMA | ADJUVANT SUNITINIB
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 06/2017, Volume 15, Issue 6, pp. 804 - 834
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell... 
LYMPH-NODE DISSECTION | TNM STAGING SYSTEM | RADICAL NEPHRECTOMY | GROWTH-FACTOR RECEPTOR | INTERFERON-ALPHA | ONCOLOGY | RANDOMIZED PHASE-II | DAYS ON/7 DAYS | NEPHRON-SPARING SURGERY | RENAL-CELL CARCINOMA | MICROVASCULAR TUMOR INVASION
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. e13502 - e13502
Journal Article
Nature Genetics, ISSN 1061-4036, 07/2016, Volume 48, Issue 7, pp. 725 - 732
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 36, pp. 3624 - 3631
Non-clear cell renal cell carcinomas (RCCs) account for up to 25% of kidney cancers and encompass distinct diseases with distinct pathologic features,... 
COLLECTING DUCT CARCINOMA | PLATINUM SALT | ONCOLOGY | MEDULLARY CARCINOMA | INTERNATIONAL SOCIETY | PHASE-II | GENOMIC CHARACTERIZATION | GENE FUSION | CLINICAL ACTIVITY | GEMCITABINE | IMMUNOHISTOCHEMISTRY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5_suppl, pp. 395 - 395
395 Background: Analgesics have been linked to an increased risk of developing renal cell carcinoma (RCC), but the evidence is mixed. Using a meta-analysis... 
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/2018, Volume 118, Issue 9, pp. 1176 - 1178
BACKGROUND: In the phase 3 METEOR trial (NCT01865747), cabozantinib significantly improved progression-free survival, overall survival, and objective response... 
ONCOLOGY | Tyrosine | Statistical analysis | Cell survival | Antiangiogenics | Kidney cancer | Fatalities | Survival | Patients | Protein-tyrosine kinase | Clear cell-type renal cell carcinoma | Vascular endothelial growth factor receptors
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 03/2018, Volume 36, Issue 9, pp. 867 - 867
Purpose The von Hippel-Lindau tumor suppressor is inactivated in the majority of clear cell renal cell carcinomas (ccRCCs), leading to inappropriate... 
HIF2-ALPHA | ONCOLOGY | PAS-B DOMAIN | TRANSCRIPTION FACTOR | CANCER | TUMORS | ORIGINAL REPORTS
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 451 - 460
The combination of an immune checkpoint inhibitor and a VEGF pathway inhibitor to treat patients with advanced renal-cell carcinoma might increase the clinical... 
TUMOR | ANTIBODY | TARGETED THERAPIES | ATEZOLIZUMAB | ONCOLOGY | SAFETY | Care and treatment | Carcinoma | Analysis | Cancer
Journal Article
by Linehan, W. Marston and Spellman, Paul T and Ricketts, Christopher J and Creighton, Chad J and Fei, Suzanne S and Davis, Caleb and Wheeler, David A and Murray, Bradley A and Schmidt, Laura and Vocke, Cathy D and Peto, Myron and Al Mamun, Abu Amar M and Shinbrot, Eve and Sethi, Anurag and Brooks, Samira and Rathmell, W. Kimryn and Brooks, Angela N and Hoadley, Katherine A and Robertson, A. Gordon and Brooks, Denise and Bowlby, Reanne and Sadeghi, Sara and Shen, Hui and Weisenberger, Daniel J and Bootwalla, Moiz and Baylin, Stephen B and Laird, Peter W and Cherniack, Andrew D and Saksena, Gordon and Haake, Scott and Li, Jun and Liang, Han and Lu, Yiling and Mills, Gordon B and Akbani, Rehan and Leiserson, Mark D.M and Raphael, Benjamin J and Anur, Pavana and Bottaro, Donald and Albiges, Laurence and Barnabas, Nandita and Choueiri, Toni K and Czerniak, Bogdan and Godwin, Andrew K and Hakimi, A. Ari and Ho, Thai H and Hsieh, James and Ittmann, Michael and Kim, William Y and Krishnan, Bhavani and Merino, Maria J and Shaw, Kenna R. Mills and Reuter, Victor E and Reznik, Ed and Shelley, Carl S and Shuch, Brian and Signoretti, Sabina and Srinivasan, Ramaprasad and Tamboli, Pheroze and Thomas, George and Tickoo, Satish and Burnett, Kenneth and Crain, Daniel and Gardner, Johanna and Lau, Kevin and Mallery, David and Morris, Scott and Paulauskis, Joseph D and Penny, Robert J and Shelton, Candace and Shelton, W. Troy and Sherman, Mark and Thompson, Eric and Yena, Peggy and Avedon, Melissa T and Bowen, Jay and Gastier-Foster, Julie M and Gerken, Mark and Leraas, Kristen M and Lichtenberg, Tara M and Ramirez, Nilsa C and Santos, Tracie and Wise, Lisa and Zmuda, Erik and Demchok, John A and Felau, Ina and Hutter, Carolyn M and Sheth, Margi and Sofia, Heidi J and Tarnuzzer, Roy and Wang, Zhining and Yang, Liming and Zenklusen, Jean C and Zhang, Jiashan and Ayala, Brenda and Baboud, Julien and Chudamani, Sudha and Liu, Jia and Lolla, Laxmi and Naresh, Rashi and ... and The Cancer Genome Atlas Research Network and Canc Genome Atlas Res Network and Cancer Genome Atlas Research Network
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 2, pp. 135 - 145
Journal Article